Enhanced Expression but Decreased Specific Activity of Matrix Metalloproteinase 10 (MMP-10) in Comparison with Matrix Metalloproteinase 3 (MMP-3) in Human Urinary Bladder Carcinoma.

MMP-10 MMP-3 biomarker cancer urinary bladder carcinoma

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
19 Aug 2021
Historique:
received: 22 06 2021
revised: 04 08 2021
accepted: 16 08 2021
entrez: 27 8 2021
pubmed: 28 8 2021
medline: 28 8 2021
Statut: epublish

Résumé

Human urinary bladder cancer is a huge worldwide oncological problem causing many deaths every year. The degradation of extracellular matrix (ECM) induced by molecules such as matrix metalloproteinases (MMPs) is one of the main factors influencing the process of metastasis origination. The MMP expression is tied to tumor aggressiveness, stage, and patient prognosis. The cleavage of constituent proteins is initiated and prolonged by matrix metalloproteinases, such as MMP-3 and MMP-10. The aim of this study was to evaluate the expression and activity of both MMPs in human urinary bladder cancer occurring at various stages of the disease. Tissue samples from patients with urinary bladder cancer were analyzed. Samples were collected from patients with a low- and high-grade cancer. Control tissue was collected from the site opposite to the tumor. DNA content, MMPs content, and activity of MMP-3 and MMP-10 were measured using ELISA and Western blot techniques. MMP-3 and MMP-10 occur in high molecular complexes in human urinary bladder in healthy and cancerous tissues. Particularly, in high-grade tumors, the content of MMP-10 prevails over MMP-3. The actual and specific activities vary in both grades of urinary bladder cancer; however, the highest activity for MMP-3 and MMP-10 was found in low-grade tissues. In conclusion, MMP-10 had a higher content, but a lower activity in all investigated tissues compared to MMP-3. Generally, obtained results demonstrated a contrary participation of MMP-3 and MMP-10 in ECM remodeling what may be crucial in the pathogenesis of human urinary bladder carcinoma.

Identifiants

pubmed: 34441979
pii: jcm10163683
doi: 10.3390/jcm10163683
pmc: PMC8397099
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Pol J Pathol. 2014 Mar;65(1):55-9
pubmed: 25119010
Genes Cancer. 2015 Nov;6(11-12):480-9
pubmed: 26807201
Biochem Pharmacol. 2008 Jan 15;75(2):346-59
pubmed: 17678629
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1925-8
pubmed: 19435861
Eur Urol. 2017 Jan;71(1):96-108
pubmed: 27370177
J Biochem Mol Biol. 2003 Jan 31;36(1):128-37
pubmed: 12542983
Hum Pathol. 2000 Jul;31(7):860-5
pubmed: 10923925
Biochemistry. 1990 Nov 6;29(44):10261-70
pubmed: 2176865
Medicine (Baltimore). 2020 Feb;99(7):e19224
pubmed: 32049862
Biol Chem. 2003 Jun;384(6):863-72
pubmed: 12887053
J Invest Dermatol. 2015 Oct;135(10):2377-2384
pubmed: 25927164
Genes (Basel). 2020 Jul 08;11(7):
pubmed: 32650441
Urol Int. 2012;89(3):342-7
pubmed: 23006800
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Drug Discov Today. 2001 May 1;6(9):478-482
pubmed: 11344033
Mol Biotechnol. 2003 Nov;25(3):241-66
pubmed: 14668538
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Urology. 2005 Apr;65(4):815-20
pubmed: 15833553
Bioorg Med Chem. 2009 Jan 15;17(2):653-9
pubmed: 19109023
Eur Urol. 2008 Aug;54(2):303-14
pubmed: 18468779
Oncotarget. 2017 May 9;8(19):32309-32321
pubmed: 28427222
Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):130-7
pubmed: 11396630
Circ Res. 2003 May 2;92(8):827-39
pubmed: 12730128
Nat Rev Urol. 2009 Nov;6(11):596-611
pubmed: 19890339
Cancer. 1996 Dec 1;78(11):2379-87
pubmed: 8941010
Curr Med Chem. 2010;17(31):3751-68
pubmed: 20846107
J Biol Chem. 1992 May 15;267(14):9612-8
pubmed: 1315762
Biomark Insights. 2007 Nov 05;2:418-27
pubmed: 19662222
Semin Cancer Biol. 2000 Dec;10(6):415-33
pubmed: 11170864
J Cell Biol. 1997 Dec 29;139(7):1861-72
pubmed: 9412478

Auteurs

Jacek Kudelski (J)

Department of Urology, Medical University of Bialystok, M. Skłodowskiej-Curie 24A St., 15-276 Białystok, Poland.

Grzegorz Młynarczyk (G)

Department of Urology, Medical University of Bialystok, M. Skłodowskiej-Curie 24A St., 15-276 Białystok, Poland.
Department of Medical Biochemistry, Medical University of Bialystok, Adama Mickiewicza 2C St., 15-089 Białystok, Poland.

Monika Gudowska-Sawczuk (M)

Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, Poland.

Barbara Mroczko (B)

Department of Biochemical Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, Poland.
Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Waszyngtona 15A St., 15-269 Bialystok, Poland.

Barbara Darewicz (B)

Department of Urology, Medical University of Bialystok, M. Skłodowskiej-Curie 24A St., 15-276 Białystok, Poland.

Marta Bruczko-Goralewska (M)

Department of Medical Biochemistry, Medical University of Bialystok, Adama Mickiewicza 2C St., 15-089 Białystok, Poland.

Krzysztof Sobolewski (K)

Department of Medical Biochemistry, Medical University of Bialystok, Adama Mickiewicza 2C St., 15-089 Białystok, Poland.

Lech Romanowicz (L)

Department of Medical Biochemistry, Medical University of Bialystok, Adama Mickiewicza 2C St., 15-089 Białystok, Poland.

Classifications MeSH